Navigation Links
Lilly Announces Senior Leadership Changes
Date:2/11/2011

INDIANAPOLIS, Feb. 11, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Sue Mahony, currently senior vice president of human resources and diversity, has been named senior vice president and president of Lilly Oncology.

In this new role she continues to report to John Lechleiter, Ph.D., Lilly chairman, president, and CEO, and she remains a member of the company's executive committee. Mahony succeeds John H. Johnson, who resigned last month.

Being promoted into Mahony's former role is Steve Fry, currently vice president of human resources for two of Lilly's business areas, bio-medicines and emerging markets. Fry now joins Lilly's executive leadership team and reports to Lechleiter. Both moves are effective immediately.

Mahony

"Sue brings a deep understanding of both the scientific and commercial aspects of our business gained through a broad range of leadership roles here at Lilly and with other major pharmaceutical companies," said Lechleiter. "Lilly has one of the largest clinical-stage pipelines of potential cancer medicines in the industry. Sue is a proven leader who will help Lilly make the most of these incredible opportunities."

Mahony joined Lilly more than 10 years ago after a decade in sales and marketing roles in the United Kingdom and Europe in oncology/hematology and cardiovascular medicine for Amgen, Bristol-Myers Squibb, and Schering-Plough. She was named general manager of Lilly Canada in 2008 after roles in global marketing and new product development, including a leadership role in the development of Cymbalta®. Mahony was also the Six Sigma leader for Lilly's sales and marketing component. She was promoted to the top human resources role in 2009.

Mahony received her bachelor's degree and Ph.D. in pharmacy, in the Cancer Research Campaign Experimental Chemotherapy Group, from Aston University in Great Britain, and holds an MBA from the London Business School.

Fry

"Steve is a human resources professional who has also played a critical role in shaping our organizational approach, including the new business areas we formed last year. His varied experiences give him a firm grasp of how our business operates in all parts of the world," said Lechleiter. "Steve will build on the momentum that Sue initiated with our diversity efforts and help ensure the development of Lilly people remains a top priority for the company."

Fry, who was the managing director of Lilly's Australian affiliate from 2004 – 2007, then served in human resources capacities as executive director for the intercontinental region and Japan until becoming vice president for bio-medicines and emerging markets. He joined Lilly in 1987 as a scientific systems analyst in the company's former Greenfield, Ind. laboratories, moving into human resources in 1992. Fry assumed a leadership role when he was selected as the director of human resources for Lilly's United Kingdom affiliate in 1998, followed by executive director positions for both Lilly's U.S. affiliate and the pharmaceutical operations area.

Fry has a bachelor's degree in business from the University of Indianapolis.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
(Date:2/12/2016)... ALISO VIEJO, Calif. , Feb. 12, 2016 /PRNewswire/ ... patient enrollment in a study to evaluate the safety ... specifically for the treatment of ruptured intracranial aneurysms.  Prof ... Bicetre University Hospital, in Paris, France ... the first patient. France ...
(Date:2/12/2016)... and SEOUL, South Korea ... Biosys­tems Menarini and Macrogen, Inc. today announced they ... and innovative procedures for precision medicine in cancer. ... Silicon Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput ... tests certified under the Clinical Laboratory Improvement Amendments ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of ... American businesses. , The increasingly modern world of instantaneous consumption proves very convenient ... energy sources such as oil and coal, which pollutes our air, water, and soil. ...
(Date:2/13/2016)... ... ... In the early or “honeymoon” stage of a relationship, couples strive to ... way to be romantic, and may exaggerate a strength or two in an effort ... , A recent study from Queendom.com , however, suggests that new couples ...
(Date:2/12/2016)... Opelousas, LA (PRWEB) , ... February 12, 2016 , ... ... of St. Landry and Evangeline Parishes. The purpose of these scholarships is to ... to encourage those individuals to seek employment within these two parishes. , “We ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... life cycle of pharmaceutical products, garnering increased attention from all stakeholders in the ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... nominations have closed for the ISE Southeast Awards 2016. Finalists and winners of ... the ISE® Southeast Executive Forum and Awards Gala on March 15, 2016 at ...
Breaking Medicine News(10 mins):